Ratings Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.36 ^USD	-7.48%		-2.86%	-86.14%

Apr. 22	JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	MT
Apr. 18	Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company appears to be poorly valued given its net asset value.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's enterprise value to sales, at 4.15 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	-86.14%	370M	C
THERMO FISHER SCIENTIFIC	+8.78%	220B	B
DANAHER CORPORATION	+8.24%	185B	B-
INTUITIVE SURGICAL, INC.	+11.16%	133B	B-
BOSTON SCIENTIFIC CORPORATION	+26.12%	107B	A-
SIEMENS HEALTHINEERS AG	+0.91%	62.91B	A-
EDWARDS LIFESCIENCES CORPORATION	+16.21%	53.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.63%	47.71B	B+
AGILENT TECHNOLOGIES, INC.	-1.11%	40.29B	A
GE HEALTHCARE TECHNOLOGIES INC.	+12.16%	39.57B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes